Page 9 - Global Impression News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Palvella Therapeutics Announces Planned Pivotal Phase 3 Study Design of QTORIN™ 3 9% Rapamycin

QTORIN™ rapamycin has potential to become first approved therapy and standard of care for Microcystic Lymphatic Malformations in U.S.; significant commercial opportunity based on an estimated more than 30,000 individuals

Marcy nanusMicrocystic lmsWesleyh kaupinenWes kaupinenJoycem tengVishala patelEuropean medicines agencyTrilon advisorsStanford university school of medicineGorlin syndrome alliancePalvella therapeutics incMicrocystic lymphatic malformationsMicrocystic lymphaticClinician global impressionBasal cell carcinomasGorlin syndrome

Virios Therapeutics Announces Positive Data Demonstrating

ATLANTA, July 17, 2023 (GLOBE NEWSWIRE) Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on.

Lucinda batemanR michael gendreauExchange commissionBateman horne centerVirios therapeutics incDrug administrationBrookings institutePost acute sequelaeOrthostatic intoleranceGlobal impressionMedical directorChief medical officerSecurities litigation reform actVirios therapeuticAnnual reportVirios therapeutics

Disc Medicine (IRON) Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin

Disc Medicine (IRON) Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

John quiselDisc medicine incEuropean hematology associationExchange commissionPeg rusconiverge scientific communicationsDisc medicineChief executive officerWill savageChief medical officerGlobal impressionErythropoietic protoporphyriaX linked protoporphyriaDisc medicinedisc medicinePrivate securities litigation reform actQuarterly report

Disc Medicine Opco : Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress - Form 8-K

Disc Medicine, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic. | June 9, 2023

Christina tartagliaJohn quiselVerge scientific communicationsExchange commissionEuropean hematology associationDisc medicine incDisc presents positive initial dataErythropoietic protoporphyriaChief executive officerWill savageChief medical officerGlobal impressionX linked protoporphyriaPrivate securities litigation reform actQuarterly reportDisc medicine opco inc stock exchange

Portfolio company Disc Medicine presents positive initial data from Phase 2 BEACON trial at EHA

Portfolio company Disc Medicine presents positive initial data from Phase 2 BEACON trial at EHA

City ofUnited kingdomIbrahim khalilSarah macleodArix bioscienceJohn quiselRobert lyneNick johnsonPowerscourt groupEuropean haematology associationEuropean hematology associationDisc medicine pressDisc medicine incDisc medicineMedicine press releasePresents positive initial data